

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA - Daratumumab with lenalidomide and dexamethasone
for untreated multiple myeloma when stem cell transplant
is unsuitable**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

No equalities issues were identified during the scoping process.
--

- | |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

NA

- | |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

NA

- | |
|--|
| 4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made? |
|--|

NA

Approved by Associate Director (name): Henry Edwards

Date: 18/03/2022